The long-range goals of this research are to elucidate mechanisms that regulate human cytomegalovirus (HCMV) gene expression at the translational level. Cells infected by HCMV continue to synthesize proteins, despite activation of host mechanisms designed to shut off translation and thereby prevent viral replication. These studies will clarify the biochemical and genetic basis for the preservation of the robust protein synthetic capacity in HCMV-infected cells. HCMV rescues replication of a vaccinia virus mutant lacking the double-stranded RNA binding protein gene E3L (VVdeltaE3L). In the absence of HCMV, cells infected with the VVdeltaE3L contain high levels of phosphorylated eIF2-alpha and RNaseL activity, and low levels of protein synthesis, viral late gene expression and viral production. HCMV infection reverses each of these properties. Using VVdeltaE3L as a means to activate the host cell antiviral responses, experiments will delineate the steps in the pathways leading to eIF2-alpha phosphorylation and RNaseL activation that are blocked by HCMV infection. The HCMV gene(s) responsible for the rescue of late gene expression and replication of VVdeltaE3L will be identified and its functional domains will be delineated. The mechanism of action of the complementing gene(s) will be elucidated and its expression properties, conservation among HCMV isolates and role in the replicative cycle will be determined. These studies will reveal new insights into the host-virus interactions that are likely to be critical determinants of the pathogenesis of HCMV disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI026672-14A1
Application #
6614800
Study Section
Virology Study Section (VR)
Program Officer
Beisel, Christopher E
Project Start
1988-08-01
Project End
2008-03-31
Budget Start
2003-04-01
Budget End
2004-03-31
Support Year
14
Fiscal Year
2003
Total Cost
$387,425
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Bayer, Avraham; Brennan, Greg; Geballe, Adam P (2018) Adaptation by copy number variation in monopartite viruses. Curr Opin Virol 33:7-12
Hickson, Sarah E; Margineantu, Daciana; Hockenbery, David M et al. (2018) Inhibition of vaccinia virus replication by nitazoxanide. Virology 518:398-405
Child, Stephanie J; Hickson, Sarah E; Bayer, Avraham et al. (2018) Antagonism of the Protein Kinase R Pathway in Human Cells by Rhesus Cytomegalovirus. J Virol 92:
Daugherty, Matthew D; Schaller, Aaron M; Geballe, Adam P et al. (2016) Evolution-guided functional analyses reveal diverse antiviral specificities encoded by IFIT1 genes in mammals. Elife 5:
Mouna, Lina; Hernandez, Eva; Bonte, Dorine et al. (2016) Analysis of the role of autophagy inhibition by two complementary human cytomegalovirus BECN1/Beclin 1-binding proteins. Autophagy 12:327-42
Carpentier, Kathryn S; Esparo, Nicolle M; Child, Stephanie J et al. (2016) A Single Amino Acid Dictates Protein Kinase R Susceptibility to Unrelated Viral Antagonists. PLoS Pathog 12:e1005966
Gray, Elizabeth E; Winship, Damion; Snyder, Jessica M et al. (2016) The AIM2-like Receptors Are Dispensable for the Interferon Response to Intracellular DNA. Immunity 45:255-66
Braggin, Jacquelyn E; Child, Stephanie J; Geballe, Adam P (2016) Essential role of protein kinase R antagonism by TRS1 in human cytomegalovirus replication. Virology 489:75-85
Carpentier, Kathryn S; Geballe, Adam P (2016) An Evolutionary View of the Arms Race between Protein Kinase R and Large DNA Viruses. J Virol 90:3280-3
Brennan, Greg; Kitzman, Jacob O; Shendure, Jay et al. (2015) Experimental Evolution Identifies Vaccinia Virus Mutations in A24R and A35R That Antagonize the Protein Kinase R Pathway and Accompany Collapse of an Extragenic Gene Amplification. J Virol 89:9986-97

Showing the most recent 10 out of 28 publications